MYL - Mylan Q3 non-GAAP EBITDA up 9%; merger with Upjohn approaches

Mylan N.V. (MYL) Q3 results:Revenues: $2,972.1M (+0.3%).Sales in Europe up 7%. Sales in North America down 5%.Net income: $185.7M (-2.2%); non-GAAP net income: $679.7M (+12.5%); EPS: $0.36 (-2.8%); non-GAAP EBITDA: $1,009.7M (+9.4%).Cash flow ops: $525.0M (+7.6%).No guidance provided.This is the final earnings release for Mylan. The company will combine with Pfizer's (PFE) Upjohn unit and will do business as Viatris in 10 days.Mylan EPS beats by $0.15, misses on revenue

For further details see:

Mylan Q3 non-GAAP EBITDA up 9%; merger with Upjohn approaches